Please ensure Javascript is enabled for purposes of website accessibility

Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't

By Brian Orelli, PhD - May 31, 2018 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sometimes press release headlines and share prices don't match up.

What happened

Shares of Clearside Biomedical (CLSD -0.60%) are down 26% at 12:47 p.m. EDT after the company announced what it called "positive topline results" from the phase 2 Tybee trial testing its steroid treatment, CLS-TA, in patients with an eye disease called diabetic macular edema.

Investors clearly had a different interpretation of the data.

Man with clenched fists on head looks at stock charts

Image source: Getty Images.

So what

Technically, they're both right.

The trial tested CLS-TA in combination with Regeneron Pharmaceuticals' Eylea, measuring patients' ability to read letters on an eye chart called the Early Treatment of Diabetic Retinopathy Trial (ETDRS) scale. Patients taking the combination gained an average of 12.3 ETDRS letters from baseline over six months. That's "positive."

But there was a control arm of patients who got Eylea alone, who gained an average of 13.5 ETDRS letters, which is a greater improvement than the combination, although it's probably still within the variance of the test, so let's call it similar efficacy.

Clearside Biomedical wants to call the tie a win because the combination treatment was give at the start of the trial and at month three, while Eylea alone was given as four monthly treatments. Fewer injections -- especially into the eye -- is something patients and their doctors can get behind, but Clearside Biomedical will have to prove that the less-frequent combination really has similar efficacy to monthly Eylea in a larger trial.

In addition to efficacy, there's also the issue of side effects, where the combination appears to be inferior -- again, keeping in mind this is a phase 2 trial with just 71 patients. Elevated intraocular pressure occurred in 8.3% of patients taking the combination compared to 2.9% of patients taking Eylea alone. Similarly, the frequency of cataracts was higher, with 5.6% of patients taking the combination developing cataracts, compared to 2.9% of patients taking Eylea alone.

Now what

Clearside Biomedical is evaluating whether to take the drug into phase 3 development, but based on the quotes from management in the press release and the "positive" headline, it seems likely the biotech will press on with the high-risk, high-reward phase 3 program.

Investors are right to discount the shares today, reducing downside risk from here until the company can show similar efficacy and that the side effects are nothing to worry about. Today's lackluster results may also be giving investors pause regarding upcoming data testing CLS-TA plus Eylea in patients with retinal vein occlusion, although the eye diseases are different enough that it's hard to make a firm conclusion on how much read-through there should be.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clearside Biomedical, Inc. Stock Quote
Clearside Biomedical, Inc.
$1.65 (-0.60%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.